JAGX has been the subject of a number of other research reports. Zacks Investment Research raised shares of Jaguar Health from a hold rating to a buy rating and set a $5.50 price target for the company in a report on Friday, June 28th. HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the company a buy rating in a report on Tuesday, July 2nd.
Shares of JAGX remained flat at $$1.61 during midday trading on Thursday. 216,907 shares of the company’s stock traded hands, compared to its average volume of 559,588. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.30 and a quick ratio of 0.18. Jaguar Health has a twelve month low of $1.55 and a twelve month high of $175.00. The business’s 50 day moving average price is $3.61.
In other Jaguar Health news, Director James J. Bochnowski purchased 180,582 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was purchased at an average price of $2.00 per share, with a total value of $361,164.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.81% of the stock is currently owned by company insiders.
About Jaguar Health
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Read More: What is a management fee?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.